Becker’s Hospital Review published its 101 Hospital and Health System Chief Pharmacy Officers to Know in 2026 this week, and the story inside the list is more important than the list itself. The pattern emerging across leading health systems is consistent and consequential: pharmacy leaders who built their credibility on medication safety, cost management, and clinical outcomes are being invited, and in some cases actively competing, to take operational ownership of domains that have nothing to do with pharmacy in the traditional sense.
What the Becker’s List Actually Reveals
The 101 CPOs featured in Becker’s 2026 list hold titles and responsibilities that would have been unrecognizable in pharmacy leadership a decade ago. The list includes pharmacists running supply chain strategy for entire health systems, pharmacists serving as chief information officers or clinical informatics leads, pharmacists heading population health programs, and pharmacists sitting at the CFO table as primary architects of value-based care financial strategy.
Two specific figures from the list illustrate how far this expansion has gone.
Mike DeCoske, PharmD, serves as Senior Vice President and Chief Pharmacy Officer at Duke University Health System, where he has expanded his scope beyond traditional pharmacy operations to include enterprise medication cost optimization and clinical supply chain oversight. He has co-authored publications on value-based pharmaceutical decision-making that frame drug formulary decisions explicitly as enterprise financial strategy, not departmental cost management.
Erin Fox, PharmD, BCPS, FASHP, serves as Chief Pharmacy Officer at University of Utah Health and built her national reputation through drug shortage monitoring work that explicitly positioned pharmacy intelligence as a national security and enterprise risk function. Her work on the ASHP drug shortage database transformed a pharmacy-specific problem into a health system operations function with strategic implications that C-suite executives across the country could directly evaluate.
These are not outliers. They represent a pattern of pharmacy leaders who demonstrated that their professional training equipped them to manage problems at enterprise scale, and who then received the organizational authority to do so.
Why the Business Case Is So Compelling to CFOs
The financial argument for expanding pharmacy leadership scope is not abstract. It flows directly from one number.
Hospital drug spend exceeded $190 billion annually in U.S. health systems as of 2025. No other clinical department manages a cost base of that magnitude with the same operational sophistication, the same clinical governance infrastructure, and the same combination of purchasing leverage, formulary control, and utilization management capability.
The pharmacy leader who frames their department’s work in enterprise financial terms rather than departmental cost terms is speaking a language CFOs speak fluently. The difference between “we reduced the pharmacy budget by 4%” and “we optimized $8 million in drug spend while improving adherence rates in our highest-cost DRG categories by 12%, reducing average length of stay by 0.4 days” is the difference between being a cost center manager and being a strategic partner. The data underlying both statements is the same. The framing determines who gets invited to the next budget meeting.
The clinical quality dimension reinforces the financial argument. Medication-related adverse events remain one of the largest drivers of preventable harm and avoidable cost in U.S. health systems, generating approximately $40 billion in avoidable costs annually. The pharmacy leader who has demonstrated measurable reduction in medication error rates, preventable readmissions attributable to medication issues, and drug-related adverse events has built a financial performance story that no other clinical department can produce with equivalent clarity of causation.
The Domains Where Pharmacy Leaders Are Expanding
Five specific enterprise domains are where pharmacy leadership expertise is proving most transferable.
Clinical informatics and decision support. Pharmacy leaders have spent decades working at the interface between clinical decision support systems, EHR medication modules, and clinical practice. The pharmacist who understands how clinical decision support alerts fire, which ones get overridden and why, and how to optimize the alert logic to improve signal-to-noise ratio without generating alert fatigue is applying exactly the analytical infrastructure knowledge that health system informatics departments need. Several health systems have placed pharmacists in CIO or clinical informatics director roles specifically because of this applied expertise.
Supply chain strategy and pharmaceutical procurement. The drug shortage landscape covered extensively in this newsletter, including the ASHP Pharmacy Forecast 2026 warning about geopolitical supply chain risk, has elevated pharmaceutical supply chain management from a procurement function to an enterprise risk function. The pharmacy leader who can model supply chain vulnerability for the health system’s top 50 dispensed medications, identify single-source generic risk, and build contingency procurement relationships is providing strategic risk management value that the CFO and COO need.
Population health and value-based care program design. The CMS ACCESS Model, covered in this newsletter’s July 5 issue, explicitly builds pharmacist coordination into its payment structure. Health systems building ACCESS and ACO participation programs need pharmacy leadership to design the medication management component of their population health strategy. The pharmacist who understands which high-risk patients generate the most preventable cost, which medication interventions produce the most measurable outcome improvement, and how to document those interventions in a format that qualifies for value-based payment is the person who belongs in the population health design room.
Revenue cycle optimization for clinical pharmacy services. As provider status legislation advances and pharmacist billing for clinical services expands, the revenue cycle infrastructure required to capture that billing is a new organizational capability most health systems have not fully built. The pharmacy leader who builds that infrastructure, including the CPT code documentation workflows, the prior authorization processes for clinical pharmacist services, and the outcomes tracking required for payer performance reporting, is creating a new revenue stream while simultaneously building an evidence base for continued scope expansion.
Enterprise risk and regulatory management. The FDA leadership vacuum, compounding regulations, 503A and 503B compliance, the peptide regulatory sequence, the GLP-1 compounding deadline, all covered in prior issues of this newsletter, represent regulatory risk domains where pharmacy expertise is the only clinical expertise that applies. The pharmacy leader who can brief the health system’s general counsel, compliance officer, and C-suite on regulatory developments affecting the pharmacy supply chain and compounding operations is filling an enterprise risk management function that no other department can provide.
The Independent Pharmacy Equivalent
For independent pharmacists, the expansion opportunity is different in scale but identical in structure.
The health system CPO who moves from managing a pharmacy budget to leading enterprise supply chain strategy is performing the same underlying move as the independent pharmacist who moves from dispensing volume to clinical services revenue. Both are demonstrating that their expertise applies to a larger problem than the one they were initially hired to solve. Both are building their credibility by delivering measurable outcomes in a domain where they previously had no formal authority. And both are ultimately making the same argument: the pharmacist’s perspective, applied systematically to a complex problem, produces better outcomes than any alternative.
The independent pharmacist who builds a CGM education program and documents A1C improvements, who runs a pharmacogenomics consultation service and tracks therapy optimization rates, who delivers Remote Patient Monitoring for hypertension patients and shows blood pressure control data, is not running a pharmacy in the traditional sense. They are running a clinical practice that happens to also dispense medications. That reframe, from dispensing operation to clinical practice, is the same reframe health system CPOs are making when they move from pharmacy budget manager to enterprise value-based care strategist.
The evidence currency this newsletter discussed in the previous issue applies directly here. The independent pharmacist who documents outcomes systematically is building the same kind of performance story that health system CPOs use to expand their organizational scope. The only difference is the audience: a payer or value-based care contract rather than a C-suite.
The Skill Set That Makes This Expansion Possible
The pharmacy leaders expanding their organizational scope share a specific combination of competencies that are worth naming explicitly, because they are buildable.
Financial literacy beyond the departmental budget. Understanding contribution margins, total cost of care calculations, DRG-level cost attribution, and value-based contract financial modeling is not standard PharmD curriculum. It is learned. The pharmacy leader who invests in health system finance literacy, whether through coursework, a health system MBA, or simply spending time with the CFO team, builds the language fluency that makes them credible in strategic conversations.
Data fluency at the enterprise level. The pharmacist who can pull their own analytics from the EHR, build a population health dashboard, and present outcome data in a format that CFOs, CMOs, and COOs can immediately interpret is doing something most pharmacists do not do. The skills required are accessible: basic SQL for EHR data extraction, visualization tools like Tableau or Power BI, and the ability to connect clinical metrics to financial outcomes. The Autonomous Pharmacy Framework, covered in this newsletter, and the data literacy issue both pointed at the same capability gap.
Strategic communication in non-pharmacy audiences. The most important competency expansion for pharmacy leaders moving into enterprise roles is the ability to communicate clinical pharmacist expertise in the language of the audience, whether that audience is a CFO, a board of trustees, a payer medical director, or a community health council. The risk management framing covered in the prior issue of this newsletter is one version of this: same clinical work, different language, different room.
Your Action This Week
Identify the one domain adjacent to your current pharmacy role where your expertise is most directly applicable and where the domain’s leaders have problems you can solve.
For a health-system pharmacist, that domain might be clinical informatics, where your daily experience with EHR medication modules makes you more useful than most informatics staff who have never dispensed a medication. Or value-based care program design, where your population health analytics skills and outcome documentation experience make you a natural partner for the team building the ACO’s pharmacist coordination infrastructure.
For an independent pharmacist, that domain might be employer health benefits, where your medication cost expertise makes you a credible partner for a local employer trying to manage a pharmacy benefit that is consuming 60% of their healthcare spend. Or community health infrastructure, where your FQHC relationships and patient population knowledge make you the right partner for an ACO seeking to demonstrate community pharmacy’s value in their value-based performance metrics.
Find where those decisions are being made in your market. Then show up with something valuable to contribute, not a request to be recognized, but a specific insight, a specific data point, a specific proposal for a pilot that addresses a problem the decision-makers are already trying to solve.
The pharmacy leaders who are running more than pharmacy didn’t wait for an invitation. They showed up where the decisions were being made and demonstrated they belonged there. The threshold the profession crossed in July 2026 means that invitation is available to any pharmacist willing to reach for it.
Sources: Becker’s Hospital Review (101 Hospital and Health System Chief Pharmacy Officers to Know in 2026, July 2026), Becker’s Hospital Review (Becker’s Pharmacy Report Weekly Coverage, July 2026), ASHP (Chief Pharmacy Officer Professional Development Resources; ASHP Practice Advancement Initiative 2030), Duke University Health System (Michael DeCoske PharmD Profile and Publications), University of Utah Health (Erin Fox PharmD Profile and Drug Shortage Database Work), AJHP / Oxford Academic (National Trends in Prescription Drug Expenditures and Projections for 2026, April 2026), American Journal of Health-System Pharmacy (Pharmacist Leadership in Enterprise Value-Based Care, 2025), Drug Channels (Hospital Pharmacy Drug Spend Analysis, 2025 Update)